Results 61 to 70 of about 47,533 (300)

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]

, 2018
BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph, Donahue, Timothy, Hines, O Joe, Hoos, William, Isacoff, William H, Rahib, Lola, Reber, Howard A, Upfill-Brown, Alexander   +7 more
core   +1 more source

KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response

Cell Death and Disease, 2022
Oxaliplatin resistance is a major challenge in the treatment of colorectal cancer (CRC). Many molecular targeted drugs for refractory CRC have been developed to solve CRC drug resistance, but their effectiveness and roles in the progression of CRC and ...
Xiaohui Shen, Yuchen Zhang, Zhuoqing Xu, Han Gao, Wenqing Feng, Wenchang Li, Yiming Miao, Zifeng Xu, Yaping Zong, Jingkun Zhao, Aiguo Lu   +10 more
doaj   +1 more source

Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma [PDF]

, 2018
In this study, our aim is to assess the role played by autophagy and its inhibition in the different PDAC cellular compartments, and its involvement in chemo-resistance using primary human pancreatic cancer-derived cells (PCC) and Cancer Associated ...
Bintz, Jennifer, Fanale, Daniele, Gayet, Odile, Iovanna, Juan Lucio, Molejon, Maria Ines, Soubeyran, Philippe, Swayden, Mirna   +6 more
core   +1 more source

TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell

Canadian Journal of Gastroenterology and Hepatology, 2021
Background. Oxaliplatin is the first-choice chemotherapy method for patients with advanced colon cancer. However, its resistance leads to treatment failure for many patients.
Guoqiong Lei, Sushun Liu, Xin Yang, Chao He   +3 more
doaj   +1 more source

Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials [PDF]

, 2012
Purpose: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC).
Allegra CJ, Amado RG, Andreas Jung, Andreyev HJ, Bazan V, Bokemeyer C, Bos JL, Boughdady IS, Cappuzzo F, Cerottini JP, Christoph C. Zielinski, De Roock W, Dominik P. Modest, Douillard JY, Finkelstein SD, Frattini M, Galina Kurteva, Heinemann V, Janja Ocvirk, Jens Neumann, Jonker DJ, Karapetis CS, Khambata-Ford S, Khosravi-Far R, Lièvre A, Maughan TS, Moosmann N, Neumann J, Ocvirk J, Regina Knittelfelder, Roth AD, Ruediger P. Laubender, Samowitz WS, Scheffzek K, Sebastian Stintzing, Thomas Brodowicz, Thomas Kirchner, Tournigand C, Tveit K, Van Cutsem E, Volker Heinemann, Zsuzsanna Papai   +41 more
core   +1 more source

Comparison of Colorectal Cancer Stem Cells and Oxaliplatin-Resistant Cells Unveils Functional Similarities

Cells, 2022
Colorectal cancer is the second most common cancer in women, the third in men, and an important cause of cancer-related mortality. Recurrence and the development of chemotherapy resistance are major hindrances for patients’ treatment.
Vanessa Rodríguez-Fanjul, Rosa Guerrero-López, Beatriz Fernández-Varas, Rosario Perona, Ana Sastre-Perona, Leandro Sastre   +5 more
doaj   +1 more source

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer

British Journal of Cancer, 2022
Abstract Background Colorectal cancer (CRC), the most common cancer type, causes high morbidity and mortality. Patients who develop drug resistance to oxaliplatin-based regimens have short overall survival. Thus, identifying molecules involved in the development of oxaliplatin resistance is critical for designing ...
Chi-Che Hsieh, Sen-Huei Hsu, Chih-Yu Lin, Hung-Jiun Liaw, Ting-Wei Li, Kuan-Ying Jiang, Nai-Jung Chiang, Shang-Hung Chen, Bo-Wen Lin, Po-Chuan Chen, Ren-Hao Chan, Peng-Chan Lin, Yu-Min Yeh, Che-Hung Shen   +13 more
openaire   +2 more sources

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5

Scientific Reports, 2022
A major reason for treatment failure of cancer is acquisition of drug resistance. The specific mechanisms underlying hepatocellular carcinoma (HCC) chemoresistance need to be fully elucidated.
Chongsheng Xia, Yurui Sun, Yang Li, Junli Ma, Jing Shi   +4 more
doaj   +1 more source

Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma [PDF]

, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Acland, Assenat, Bazhin, Carbone, Chaput, Chen, Chouaib, Danenberg, David, Dyson, El-Deiry, Gallick, Gelovani, Ghansah, Giese, Gil, Gress, Gribben, Hao, Hao, Hao, Henson, Jemal, Kiessling, Kroemer, Kroemer, Kroemer, Levi, Luo, Mi, Moses, Plate, Powis, Powis, Powis, Ravichandran, Ricci, Rodeck, Sarker, Schuler, Semenza, Singh, Spisek, Tani, Vandenabeele, Wang, Wang, Zitvogel, Zitvogel, Zitvogel   +49 more
core   +1 more source